Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers
NCT04312243Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2020
- Primary completion
- Jan 2022
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 2 trial of nitric oxide in coronavirus disease 2019 (COVID-19), sponsored by Massachusetts General Hospital. Started Apr 2020; status: terminated.
02
Drugs
nitric oxide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04312243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04312243.